Alnuctamab, Alnuctamab, CC-92480 0.3 mg, CC-92480 0.4 mg, CC-92480 0.6 mg, DEXAMETHASONE, CC-92480 0.2 mg
CA058-002
Phase 2 small_molecule active
Quick answer
Alnuctamab, Alnuctamab, CC-92480 0.3 mg, CC-92480 0.4 mg, CC-92480 0.6 mg, DEXAMETHASONE, CC-92480 0.2 mg for Relapsed and/or Refractory Multiple Myeloma is a Phase 2 program (small_molecule) at Celgene Europe Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Celgene Europe Limited
- Indication
- Relapsed and/or Refractory Multiple Myeloma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active